Glenn E. Kirsch
Research Subjects
Glenn E. Kirsch has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Arthur M. Brown
ChanTest Corporation
5 shared publicationsAndrew Bruening-Wright
2 shared publicationsA A Timur
Department of Molecular Cardiology, Lerner Research Institute, and Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
1 shared publicationAndrew Bruening‐Wright
ChanTest Corporation Cleveland Ohio
1 shared publicationAntonio E. Lacerda
1 shared publicationArthur M Brown
From the ChanTest Corporation, Cleveland, OH
1 shared publication
Latest Publications
- Open Access
- 1 March 2014
- Published by SAGE Publications in ASSAY and Drug Development Technologies
- Vol. 12 (2) , 110-119
Evaluating State Dependence and Subtype Selectivity of Calcium Channel Modulators in Automated Electrophysiology Assays
Voltage-gated Ca 2+ channels play essential roles in control of neurosecretion and muscle contraction. The pharmacological significance of Ca v channels stem from their identification as the molecular targets of calcium blockers used in the treatment of cardiovascular diseases, such as hypertension, angina, and arrhythmia, and neurologic diseases, such as pain and seizure. It has been proposed that state-dependent Ca v inhibitors, that is, those that preferentially bind to channels in open or inactivated states, may improve the therapeutic window over relatively state-independent Ca v inhibitors. High-throughput fluorescent-based functional assays have been useful in screening chemical libraries to identify Ca v inhibitors. However, hit confirmation, mechanism of action, and subtype selectivity are better suited to automated patch clamp assays that have sufficient capacity to handle the volume of compounds identified during screening, even of modest sized libraries (≤500,000 compounds), and the flexible voltage control that allows evaluation of state-dependent drug blocks. IonWorks™ Barracuda (IWB), the newest generation of IonWorks instruments, provides the opportunity to accelerate the Ca v drug discovery studies in an automated patch clamp platform in 384-well format capable of medium throughput screening and profiling studies. We have validated hCa v 1.2, hCa v 2.1, hCa v 2.2, and hCa v 3.2 channels assays on the IWB platform (population patch clamp mode) and demonstrated that the biophysical characteristics of the channels (activation, inactivation, and steady-state inactivation) obtained with the IWB system are consistent with known subtype-specific characteristics. Using standard reference compounds (nifedipine, BAY K8644, verapamil, mibefradil, and pimozide), we demonstrated subtype-selective and state- and use-dependent characteristics of drug–channel interactions. Here we describe the design and validation of novel robust high-throughput Ca v channel assays on the IWB platform. The assays can be used to screen focused compound libraries for state-dependent Ca v channel antagonists, to prioritize compounds for potency or to counterscreen for Ca v subtype selectivity.
- 1 March 2014
- Published by SAGE Publications in ASSAY and Drug Development Technologies
- Vol. 12 (2) , 110-119
Open AccessEvaluating State Dependence and Subtype Selectivity of Calcium Channel Modulators in Automated Electrophysiology Assays
Voltage-gated Ca 2+ channels play essential roles in control of neurosecretion and muscle contraction. The pharmacological significance of Ca v channels stem from their identification as the molecular targets of calcium blockers used in the treatment of cardiovascular diseases, such as hypertension, angina, and arrhythmia, and neurologic diseases, such as pain and seizure. It has been proposed that state-dependent Ca v inhibitors, that is, those that preferentially bind to channels in open or inactivated states, may improve the therapeutic window over relatively state-independent Ca v inhibitors. High-throughput fluorescent-based functional assays have been useful in screening chemical libraries to identify Ca v inhibitors. However, hit confirmation, mechanism of action, and subtype selectivity are better suited to automated patch clamp assays that have sufficient capacity to handle the volume of compounds identified during screening, even of modest sized libraries (≤500,000 compounds), and the flexible voltage control that allows evaluation of state-dependent drug blocks. IonWorks™ Barracuda (IWB), the newest generation of IonWorks instruments, provides the opportunity to accelerate the Ca v drug discovery studies in an automated patch clamp platform in 384-well format capable of medium throughput screening and profiling studies. We have validated hCa v 1.2, hCa v 2.1, hCa v 2.2, and hCa v 3.2 channels assays on the IWB platform (population patch clamp mode) and demonstrated that the biophysical characteristics of the channels (activation, inactivation, and steady-state inactivation) obtained with the IWB system are consistent with known subtype-specific characteristics. Using standard reference compounds (nifedipine, BAY K8644, verapamil, mibefradil, and pimozide), we demonstrated subtype-selective and state- and use-dependent characteristics of drug–channel interactions. Here we describe the design and validation of novel robust high-throughput Ca v channel assays on the IWB platform. The assays can be used to screen focused compound libraries for state-dependent Ca v channel antagonists, to prioritize compounds for potency or to counterscreen for Ca v subtype selectivity.
- 31 October 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 62 (2) , e8
Stem cell-derived human cardiomyocyte action potential assay for cardiac risk evaluation
- 31 October 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 62 (2) , e8
Stem cell-derived human cardiomyocyte action potential assay for cardiac risk evaluation
- 1 October 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (4) , 420-430
Increased Cardiac Risk in Concomitant Methadone and Diazepam Treatment: Pharmacodynamic Interactions in Cardiac Ion Channels
Methadone, a synthetic opioid for treatment of chronic pain and withdrawal from opioid dependence, has been linked to QT prolongation, potentially fatal torsades de pointes, and sudden cardiac death. Concomitant use of diazepam or other benzodiazepines in methadone maintenance treatment can increase the risk of sudden death. Therefore, we determined the effects of methadone and diazepam singly and in combination on cardiac action potentials (APs) and on the major ion channels responsible for cardiac repolarization. Using patch clamp recording in human stem cell-derived cardiomyocytes and stably transfected mammalian cells, we found that methadone produced concentration-dependent AP prolongation and ion channel block at low micromolar concentrations: hERG (IC50 = 1.7 μM), hNav1.5 (11.2 μM tonic block; 5.5 μM phasic block), and hCav1.2 (26.7 μM tonic block; 7.7 μM phasic block). Methadone was less potent in hKv4.3/hKChIP2.2 (IC50 = 39.0 μM) and hKvLQT1/hminK (53.3 μM). In contrast, diazepam blocked channels only at much higher concentrations and had no effect on AP duration at 1 μM. However, coadministration of 1-μM diazepam with methadone caused a statistically significant increase in AP duration and a 4-fold attenuation of hNav1.5 block (IC50 values were 44.2 μM and 26.6 μM, respectively, for tonic and phasic block), with no significant effect on methadone-induced block of hERG, hCav1.2, hKv4.3/hKChIP2.2, and hKvLQT1/hminK channels. Thus, although diazepam alone does not prolong the QT interval, the relief of methadone-induced Na+ channel block may leave hERG K+ channel block uncompensated, thereby increasing cardiac risk.
- 1 October 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (4) , 420-430
Increased Cardiac Risk in Concomitant Methadone and Diazepam Treatment: Pharmacodynamic Interactions in Cardiac Ion Channels
Methadone, a synthetic opioid for treatment of chronic pain and withdrawal from opioid dependence, has been linked to QT prolongation, potentially fatal torsades de pointes, and sudden cardiac death. Concomitant use of diazepam or other benzodiazepines in methadone maintenance treatment can increase the risk of sudden death. Therefore, we determined the effects of methadone and diazepam singly and in combination on cardiac action potentials (APs) and on the major ion channels responsible for cardiac repolarization. Using patch clamp recording in human stem cell-derived cardiomyocytes and stably transfected mammalian cells, we found that methadone produced concentration-dependent AP prolongation and ion channel block at low micromolar concentrations: hERG (IC50 = 1.7 μM), hNav1.5 (11.2 μM tonic block; 5.5 μM phasic block), and hCav1.2 (26.7 μM tonic block; 7.7 μM phasic block). Methadone was less potent in hKv4.3/hKChIP2.2 (IC50 = 39.0 μM) and hKvLQT1/hminK (53.3 μM). In contrast, diazepam blocked channels only at much higher concentrations and had no effect on AP duration at 1 μM. However, coadministration of 1-μM diazepam with methadone caused a statistically significant increase in AP duration and a 4-fold attenuation of hNav1.5 block (IC50 values were 44.2 μM and 26.6 μM, respectively, for tonic and phasic block), with no significant effect on methadone-induced block of hERG, hCav1.2, hKv4.3/hKChIP2.2, and hKvLQT1/hminK channels. Thus, although diazepam alone does not prolong the QT interval, the relief of methadone-induced Na+ channel block may leave hERG K+ channel block uncompensated, thereby increasing cardiac risk.
- 31 October 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 60 (2) , 243
hERG vs. APD/QT results often discordant: Fast and accurate repolarization screen a necessity early in development
- 31 October 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 60 (2) , 243
hERG vs. APD/QT results often discordant: Fast and accurate repolarization screen a necessity early in development
- 28 February 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 59 (1) , 29-34
Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability
- 28 February 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 59 (1) , 29-34
Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability
- 1 September 2004
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 50 (2) , 93-101
Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern
- 1 September 2004
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 50 (2) , 93-101
Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern
- Open Access
- 30 April 2004
- Published by BMJ in Journal of Medical Genetics
- Vol. 41 (5) , e66
The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel
Long QT syndrome (LQTS) is a prototypic arrhythmic disorder that is characterised by prolonged QT interval (or QTc) on electrocardiograms (ECGs), syncope, and sudden death from episodic ventricular tachyarrhythmias, specifically torsade de pointes.1–4 LQTS causes sudden deaths in young, otherwise healthy, individuals, and in many cases the first symptom is sudden death. Both genetic and acquired factors contribute to the pathogenesis of LQTS. Predisposing genetic mutations have been identified in six genes. These include the cardiac potassium channel genes KvLQT1 or KCNQ1 (chromosome 11p15.5, LQT1),5–7 HERG or KCNH2 (7q35–36, LQT2),8 KCNE1 (21q22, LQT5),9,10 and KCNE2 (21q22, LQT6),11 the cardiac sodium channel gene SCN5A (3p21–24, LQT3),12,13 and the non-ion channel ankyrin-B gene encoding a protein that links ion channels to the cytoskeleton (4q25–27, LQT4).14 Acquired long QT syndrome (aLQTS) is LQTS caused by factors such as bradycardia, cardiac ischaemia, metabolic abnormalities (including hypocalaemia and hypomagnesaemia), starvation (anorexia nervosa), and various medical manipulations and medications including general anaesthetics, antibiotics, antihistamines, and ironically anti-arrhythmic agents.15,16 Acquired LQTS is common, with a population prevalence rate of up to 8%.17 Because almost all cases of acquired LQTS are sporadic, genetic analysis of acquired LQTS has been lagging behind inherited LQTS. However, there has recently been increased interest in determining the genetic basis of acquired LQTS by studying genes causing inherited LQTS.18–21 We carried out a similar analysis in this study. Voltage gated sodium channels are transmembrane proteins responsible for generating cardiac action potentials, and for rapid conduction of electrical signals through cardiac tissues. The cardiac sodium channel is a large protein of 2016 amino acids encoded by the SCN5A gene.22 The cardiac sodium channel consists of a pore forming α-subunit composed of four homologous domains (I–IV), each containing …
- 30 April 2004
- Published by BMJ in Journal of Medical Genetics
- Vol. 41 (5) , e66
Open AccessThe common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel
Long QT syndrome (LQTS) is a prototypic arrhythmic disorder that is characterised by prolonged QT interval (or QTc) on electrocardiograms (ECGs), syncope, and sudden death from episodic ventricular tachyarrhythmias, specifically torsade de pointes.1–4 LQTS causes sudden deaths in young, otherwise healthy, individuals, and in many cases the first symptom is sudden death. Both genetic and acquired factors contribute to the pathogenesis of LQTS. Predisposing genetic mutations have been identified in six genes. These include the cardiac potassium channel genes KvLQT1 or KCNQ1 (chromosome 11p15.5, LQT1),5–7 HERG or KCNH2 (7q35–36, LQT2),8 KCNE1 (21q22, LQT5),9,10 and KCNE2 (21q22, LQT6),11 the cardiac sodium channel gene SCN5A (3p21–24, LQT3),12,13 and the non-ion channel ankyrin-B gene encoding a protein that links ion channels to the cytoskeleton (4q25–27, LQT4).14 Acquired long QT syndrome (aLQTS) is LQTS caused by factors such as bradycardia, cardiac ischaemia, metabolic abnormalities (including hypocalaemia and hypomagnesaemia), starvation (anorexia nervosa), and various medical manipulations and medications including general anaesthetics, antibiotics, antihistamines, and ironically anti-arrhythmic agents.15,16 Acquired LQTS is common, with a population prevalence rate of up to 8%.17 Because almost all cases of acquired LQTS are sporadic, genetic analysis of acquired LQTS has been lagging behind inherited LQTS. However, there has recently been increased interest in determining the genetic basis of acquired LQTS by studying genes causing inherited LQTS.18–21 We carried out a similar analysis in this study. Voltage gated sodium channels are transmembrane proteins responsible for generating cardiac action potentials, and for rapid conduction of electrical signals through cardiac tissues. The cardiac sodium channel is a large protein of 2016 amino acids encoded by the SCN5A gene.22 The cardiac sodium channel consists of a pore forming α-subunit composed of four homologous domains (I–IV), each containing …
- Open Access
- 1 December 2000
- Published by Wiley in Current Protocols in Pharmacology
- Vol. 11 (1) , 11.12.1-11.12.26
Functional Characterization of Human Stem Cell–Derived Cardiomyocytes
Cardiac toxicity is a leading contributor to late stage attrition in the drug discovery process and to withdrawal of approved drugs from the market. In vitro assays that enable earlier and more accurate testing for cardiac risk provide early stage predictive indicators that aid in mitigating risk. Human cardiomyocytes, the most relevant subjects for early stage testing, are severely limited in supply, but human stem cell–derived cardiomyocytes (SC‐hCM) are readily available from commercial sources and are increasingly used in academic research, drug discovery, and safety pharmacology. As a result, SC‐hCM electrophysiology has become a valuable tool for assessing cardiac risk associated with drug administration. Described in this unit are techniques for recording individual sodium, calcium, and potassium currents, as well as single‐cell action potentials and impedance recordings from contracting syncytia of thousands of interconnected cells.Curr. Protoc. Pharmacol. 64:11.12.1‐11.12.26. © 2014 by John Wiley & Sons, Inc.
- 1 December 2000
- Published by Wiley in Current Protocols in Pharmacology
- Vol. 11 (1) , 11.12.1-11.12.26
Open AccessFunctional Characterization of Human Stem Cell–Derived Cardiomyocytes
Cardiac toxicity is a leading contributor to late stage attrition in the drug discovery process and to withdrawal of approved drugs from the market. In vitro assays that enable earlier and more accurate testing for cardiac risk provide early stage predictive indicators that aid in mitigating risk. Human cardiomyocytes, the most relevant subjects for early stage testing, are severely limited in supply, but human stem cell–derived cardiomyocytes (SC‐hCM) are readily available from commercial sources and are increasingly used in academic research, drug discovery, and safety pharmacology. As a result, SC‐hCM electrophysiology has become a valuable tool for assessing cardiac risk associated with drug administration. Described in this unit are techniques for recording individual sodium, calcium, and potassium currents, as well as single‐cell action potentials and impedance recordings from contracting syncytia of thousands of interconnected cells.Curr. Protoc. Pharmacol. 64:11.12.1‐11.12.26. © 2014 by John Wiley & Sons, Inc.